The Zhitong Finance App learned that BlossomHill Therapeutics is a biotechnology company whose pipeline has advanced to the second phase of clinical trials, focusing on developing small-molecule anti-cancer therapies. The company submitted a prospectus to the US Securities and Exchange Commission (SEC) on Friday to raise up to $100 million through an initial public offering (IPO).

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that BlossomHill Therapeutics is a biotechnology company whose pipeline has advanced to the second phase of clinical trials, focusing on developing small-molecule anti-cancer therapies. The company submitted a prospectus to the US Securities and Exchange Commission (SEC) on Friday to raise up to $100 million through an initial public offering (IPO).